Headlines about Five Prime Therapeutics (NASDAQ:FPRX) have been trending somewhat positive recently, according to Accern Sentiment Analysis. Accern identifies positive and negative news coverage by reviewing more than twenty million blog and news sources. Accern ranks coverage of public companies on a scale of negative one to one, with scores closest to one being the most favorable. Five Prime Therapeutics earned a media sentiment score of 0.12 on Accern’s scale. Accern also assigned news coverage about the biotechnology company an impact score of 46.7499508227973 out of 100, meaning that recent news coverage is somewhat unlikely to have an effect on the company’s share price in the next several days.
Here are some of the news articles that may have effected Accern’s rankings:
A number of equities research analysts have commented on FPRX shares. Royal Bank of Canada lifted their target price on Five Prime Therapeutics from $41.00 to $50.00 and gave the company an “outperform” rating in a research report on Monday, November 6th. BidaskClub downgraded Five Prime Therapeutics from a “hold” rating to a “sell” rating in a research report on Saturday, December 9th. BMO Capital Markets upgraded Five Prime Therapeutics from a “market perform” rating to an “outperform” rating in a research report on Monday, October 16th. Jefferies Group restated a “buy” rating and issued a $52.00 target price on shares of Five Prime Therapeutics in a research report on Tuesday, September 12th. Finally, Zacks Investment Research upgraded Five Prime Therapeutics from a “sell” rating to a “buy” rating and set a $49.00 target price on the stock in a research report on Monday, October 16th. One research analyst has rated the stock with a sell rating, two have assigned a hold rating and six have given a buy rating to the company. Five Prime Therapeutics has a consensus rating of “Buy” and an average target price of $64.00.
Shares of Five Prime Therapeutics (FPRX) traded down $0.09 during midday trading on Friday, hitting $21.84. The stock had a trading volume of 225,403 shares, compared to its average volume of 562,180. Five Prime Therapeutics has a twelve month low of $19.73 and a twelve month high of $52.98. The firm has a market capitalization of $631.83, a PE ratio of -4.32 and a beta of 3.91.
Five Prime Therapeutics (NASDAQ:FPRX) last issued its quarterly earnings data on Monday, November 6th. The biotechnology company reported ($1.54) earnings per share for the quarter, missing the Zacks’ consensus estimate of ($1.35) by ($0.19). Five Prime Therapeutics had a negative net margin of 408.42% and a negative return on equity of 41.57%. The firm had revenue of $8.33 million during the quarter, compared to analyst estimates of $16.16 million. During the same period in the previous year, the firm posted ($0.72) earnings per share. The company’s quarterly revenue was up 24.7% compared to the same quarter last year. research analysts expect that Five Prime Therapeutics will post -5.56 earnings per share for the current fiscal year.
In other news, Director William R. Ringo sold 600 shares of Five Prime Therapeutics stock in a transaction on Wednesday, November 1st. The stock was sold at an average price of $45.33, for a total value of $27,198.00. Following the completion of the sale, the director now directly owns 600 shares of the company’s stock, valued at $27,198. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is available at this link. Insiders own 6.50% of the company’s stock.
TRADEMARK VIOLATION NOTICE: This story was first published by Equities Focus and is the property of of Equities Focus. If you are accessing this story on another publication, it was stolen and reposted in violation of international copyright & trademark laws. The correct version of this story can be viewed at https://www.equitiesfocus.com/2018/01/07/five-prime-therapeutics-fprx-earns-news-sentiment-rating-of-0-12.html.
Five Prime Therapeutics Company Profile
Five Prime Therapeutics, Inc is a clinical-stage biotechnology company focused on discovering and developing protein therapeutics. The Company’s product candidates include Cabiralizumab (FPA008), which is an antibody that inhibits colony stimulating factor-1 receptor, that it is studying in clinical trials as a monotherapy in pigmented villonodular synovitis, and in multiple cancers in combination with programmed-death 1 immune checkpoint inhibitor, Opdivo; FPA144, which is an antibody that inhibits fibroblast growth factor receptor 2b, that it is initially developing to treat patients with gastric (stomach) cancer and is in a Phase I clinical trial, and FP-1039, which is a fusion protein that traps and neutralizes cancer-promoting fibroblast growth factors, involved in cancer cell proliferation and new blood vessel formation and is in Phase Ib clinical development to treat patients with malignant pleural mesothelioma.
Receive News & Ratings for Five Prime Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Five Prime Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.